viru
vaccin
immunogen
suffici
stabl
safe
suitabl
induc
longlast
immun
meet
requir
vaccin
studi
need
provid
comprehens
understand
protect
role
antivir
b
tcellmedi
immun
respons
ii
complex
plastic
major
viral
antigen
iii
viru
molecular
biolog
pathogenesi
mani
type
vaccin
includ
subunit
vaccin
wholeinactiv
viru
vector
liveattenu
viru
vaccin
featur
specif
advantag
limit
nonliv
viru
vaccin
clear
advantag
safe
stabl
may
caus
side
effect
less
efficaci
compar
liveattenu
viru
vaccin
case
latter
induc
longlast
immun
may
requir
special
safeti
measur
prevent
revers
highli
virul
virus
follow
vaccin
chapter
summar
recent
progress
develop
coronaviru
cov
vaccin
focus
two
zoonot
cov
sever
acut
respiratori
syndrom
cov
sarscov
middl
east
respiratori
syndrom
cov
caus
deadli
diseas
epidem
human
develop
attenu
viru
vaccin
combat
infect
caus
highli
pathogen
cov
larg
base
identif
character
viral
virul
protein
exampl
interfer
innat
adapt
immun
respons
involv
interact
specif
cell
type
macrophag
dendrit
epitheli
cell
lymphocyt
therebi
modul
antivir
host
respons
viral
pathogenesi
potenti
result
deleteri
side
effect
follow
vaccin
four
common
human
coronavirus
cov
endem
human
popul
first
two
cov
known
sinc
emerg
sever
acut
respiratori
syndrom
cov
sarscov
led
activ
search
novel
cov
identif
respect
van
der
hoek
et
al
woo
et
al
common
human
cov
gener
associ
rel
mild
clinic
symptom
caus
selflimit
upper
respiratori
tract
diseas
common
cold
walsh
et
al
case
common
cov
may
also
associ
sever
pathogenesi
lower
respiratori
tract
bronchiol
pneumonia
pene
et
al
van
der
hoek
et
al
woo
et
al
human
cov
caus
seriou
diseas
young
elderli
immunocompromis
individu
may
lead
exacerb
preexist
condit
asthma
chronic
obstruct
pulmonari
diseas
frequent
requir
hospit
mayer
et
al
varkey
varkey
consid
preval
virus
rang
around
popul
infect
childhood
recurr
infect
occur
throughout
life
zhou
et
al
common
human
cov
repres
signific
burden
public
health
recent
two
previous
unknown
anim
cov
emerg
shown
caus
deadli
diseas
human
first
sarscov
emerg
southern
china
spread
around
globe
late
earli
infect
least
peopl
kill
nearli
infect
individu
lee
et
al
second
middl
east
respiratori
syndrom
cov
merscov
first
report
middl
east
still
ongo
report
sporad
case
particularli
saudi
arabia
unit
arab
emir
viru
caus
close
laboratoryconfirm
case
result
death
caus
import
outbreak
korea
start
may
lead
confirm
case
death
toll
accord
world
health
organ
http
wwwwhointemerg
merscoven
current
treatment
strategi
sar
mer
discuss
discoveri
develop
new
virusbas
hostbas
therapeut
option
cov
infect
review
recent
zumla
et
al
chapter
mainli
focu
develop
vaccin
suitabl
prevent
infect
caus
highli
pathogen
cov
particularli
sarscov
merscov
human
date
wide
rang
vaccin
candid
develop
virus
includ
subunit
wholeinactiv
viru
dna
vector
vaccin
see
review
du
jiang
enjuan
et
al
zhang
et
al
howev
mani
case
vaccin
found
induc
antibodydepend
enhanc
infect
adei
eosinophilia
contrast
liveattenu
vaccin
long
histori
success
frequent
use
vaccin
human
chapter
focus
recent
develop
next
gener
liveattenu
vaccin
base
recombin
virus
attenu
virus
gener
reli
previou
identif
gene
involv
viral
virul
specif
host
often
gene
encod
protein
antagon
innat
immun
respons
delet
lead
recombin
virus
attenu
virul
therefor
may
develop
candid
vaccin
timelin
bench
research
approv
vaccin
use
gener
year
papaneri
et
al
use
genet
engin
virus
may
significantli
reduc
time
cost
requir
vaccin
develop
product
chapter
specif
featur
promis
vaccin
candid
meet
earlier
criteria
review
cov
contain
largest
genom
known
among
rna
virus
consist
singlestrand
positivesens
rna
molecul
around
kb
length
fig
de
groot
et
al
similar
cellular
mrna
contain
cap
polyadenyl
end
termin
twothird
genom
contain
two
overlap
open
read
frame
orf
fig
translat
yield
polyprotein
ribosom
frameshift
allow
translat
yield
ziebuhr
togeth
polyprotein
coand
posttransl
process
nonstructur
protein
nsp
involv
viral
genom
replic
subgenom
mrna
synthesi
third
genom
encod
seri
structur
protein
order
genusspecif
protein
vari
number
among
differ
cov
member
fig
de
groot
et
al
sola
et
al
human
belong
genu
alphacoronaviru
sarscov
merscov
belong
genu
betacoronaviru
although
overal
genom
organ
conserv
among
coronaviru
genera
member
viru
famili
encod
uniqu
set
genusspecif
protein
fig
gener
involv
modul
pathogenesi
neutral
monoclon
antibodi
mab
repres
promis
therapeut
strategi
emerg
cov
infect
fulli
human
neutral
antibodi
may
develop
use
differ
technolog
appli
therapeut
prophylact
agent
jiang
et
al
tang
et
al
ter
meulen
et
al
ying
et
al
zhang
et
al
zhu
et
al
special
interest
potent
human
crossreact
neutral
antibodi
specif
sarscov
pascal
et
al
sinc
antibodi
target
receptorbind
domain
spike
glycoprotein
antigen
variabl
within
gene
among
human
anim
strain
must
consid
design
broadspectrum
neutral
molecul
ying
et
al
combin
mab
target
differ
epitop
may
use
prevent
emerg
escap
mutant
potenti
gener
synergist
neutral
effect
ying
et
al
line
passiv
immunotherapi
mous
dromedari
immun
serum
shown
protect
anim
model
sarscov
subbarao
et
al
merscov
zhao
et
al
respect
suggest
approach
may
use
prophylact
therapeut
infect
patient
neutral
antibodi
induc
glycoprotein
provid
complet
protect
lethal
cov
infect
sui
et
al
moreov
invers
correl
observ
iga
secret
merscov
infect
patient
suggest
virusspecif
iga
product
may
suitabl
tool
evalu
potenc
candid
vaccin
merscov
howev
iga
respons
short
live
patient
contrast
virusspecif
memori
cell
persist
year
sarscov
infect
time
memori
b
cell
virusspecif
antibodi
undetect
yang
et
al
shown
memori
cell
specif
immunodomin
epitop
substanti
protect
age
mice
lethal
sarscov
infect
channappanavar
et
al
challeng
memori
cell
produc
effector
cytokin
interferon
gamma
tumor
necrosi
factor
alpha
interleukin
cytolyt
molecul
reduc
viral
load
lung
howev
dysregul
inflammatori
mediat
includ
type
ifn
inflammatori
monocytemacrophag
respons
caus
lethal
pneumonia
sarscovinfect
mice
therefor
consid
vaccin
design
minim
immunopatholog
addit
protect
effect
mediat
memori
cell
sarscovspecif
cell
antibodi
respons
like
necessari
complet
protect
requir
tcell
respons
merscov
protect
also
suggest
immun
experi
macaqu
muthumani
et
al
therefor
effect
protect
cov
vaccin
elicit
antibodi
respons
also
specif
memori
cell
inform
complex
cov
serotyp
crucial
predict
whether
antibodi
previou
cov
infect
specif
vaccin
may
protect
reinfect
import
implic
vaccin
design
neutral
antibodi
therapi
antigen
variabl
protein
major
target
neutral
antibodi
extrem
low
differ
merscov
strain
drosten
et
al
recent
serolog
studi
use
infecti
merscov
isol
collect
patient
saudi
arabia
show
signific
differ
serum
neutral
indic
isol
belong
serotyp
base
data
seem
like
gene
current
circul
merscov
interchang
candid
vaccin
formul
potenti
relev
neutral
antibodi
direct
envelop
protein
remain
studi
merscov
close
relat
virus
isol
camel
bat
belong
viral
speci
bat
virus
root
phylogenet
tree
like
viru
circul
camel
acquir
bat
repres
origin
virus
identifi
human
past
year
recombin
event
within
spike
gene
viral
ancestor
like
involv
emerg
merscov
therefor
camel
may
serv
reservoir
mainten
diversif
merscov
respons
human
infect
sabir
et
al
result
genet
variabl
may
lead
addit
antigen
divers
obviou
consequ
vaccin
design
sarscov
differ
immunolog
betacoronavirus
littl
crossreact
antivir
antibodi
hou
et
al
develop
vaccin
candid
suitabl
provid
broad
protect
address
divers
main
immunogen
determin
protein
zhou
et
al
exampl
sarscovspecif
domain
protein
found
contain
epitop
critic
determin
sensit
given
viru
neutral
antibodi
specif
epitop
variant
epitop
found
sarslikecov
civet
cat
human
sarscov
evolv
epidem
major
sarscov
first
outbreak
sensit
antibodi
strain
isol
index
patient
second
outbreak
resist
confirm
import
protein
natur
antigen
variabl
elicit
neutral
antibodi
respons
sui
et
al
sarscov
glycoprotein
major
target
protect
immun
vivo
two
specif
human
mab
recogn
protein
exhibit
potent
crossreact
isol
two
sar
outbreak
palm
civet
bat
strain
zhu
et
al
combin
two
neutral
mab
could
prevent
emerg
neutral
escap
mutant
least
attenu
viral
virul
vivo
howev
although
neutral
mab
direct
epitop
locat
interfac
viral
protein
cellular
receptor
angiotensinconvert
enzym
prove
great
potenc
breadth
neutral
multipl
viral
strain
sui
et
al
singl
combin
use
one
two
mab
respect
fail
prevent
emerg
antibodi
escap
variant
therefor
use
one
two
neutral
mab
target
structur
flexibl
sarscov
epitop
may
limit
valu
vivo
immunotherapi
combin
neutral
mab
bind
second
conserv
epitop
low
structur
plastic
suitabl
anim
model
reproduc
patholog
caus
human
cov
requir
studi
pathogenesi
vaccin
test
unfortun
appropri
anim
model
develop
date
four
common
human
cov
transgen
tg
mous
model
express
human
aminopeptidas
n
gener
suitabl
pathogenesi
studi
base
immunodefici
mice
lassnig
et
al
mous
model
extens
use
studi
human
cov
caus
lethal
infect
mice
jacomi
talbot
howev
follow
inocul
mice
respiratori
isol
viru
found
adapt
rapidli
grow
brain
tissu
viral
rna
remain
nearli
undetect
lung
butler
et
al
stjean
et
al
suggest
model
reproduc
respiratori
patholog
seen
human
limit
valu
studi
virusinduc
patholog
use
anim
model
sarscov
merscov
studi
patholog
human
recent
review
includ
clinic
symptom
viral
replic
patholog
human
nonhuman
primat
nhp
rabbit
ferret
marmoset
hamster
mice
gretebeck
subbarao
van
doremalen
munster
addit
model
merscov
base
dromedari
camel
anim
speci
also
report
falzarano
et
al
haagman
et
al
van
doremalen
munster
larg
size
lack
clear
clinic
sign
diseas
make
camel
less
suitabl
model
studi
merscov
patholog
marmoset
show
clinic
sign
follow
infect
merscov
viru
case
research
anim
appropri
reagent
suitabl
character
immun
respons
scarc
avail
limit
use
model
system
van
doremalen
munster
hamster
natur
infect
merscov
larg
prevent
use
anim
model
merscov
proteinmedi
bind
receptor
human
dipeptidyl
involv
interact
amino
acid
residu
appropri
replac
five
residu
differ
hamster
human
render
hamster
function
receptor
merscov
van
doremalen
et
al
thu
far
tg
hamster
use
due
lack
specif
gene
target
tool
avail
system
situat
may
chang
hamster
suscept
merscov
might
develop
suitabl
anim
model
merscovinduc
diseas
remain
unclear
present
merscov
abl
infect
rabbit
caus
histopatholog
clinic
symptom
although
viru
detect
lung
viru
shed
upper
respiratori
tract
provid
possibl
rout
merscov
transmiss
anim
speci
haagman
et
al
clearli
larg
size
rabbit
also
limit
use
contain
laboratori
mice
ideal
model
pathogenesi
studi
mani
virus
small
size
avail
suitabl
genom
immunolog
reagent
key
differ
sarscov
merscov
sarscov
infect
sever
strain
mice
wherea
merscov
coleman
et
al
gretebeck
subbarao
standard
procedur
adapt
sarscov
merscov
grow
mice
reproduc
diseas
caus
human
strategi
directli
appli
case
sarscov
use
convent
mous
strain
without
need
tg
mice
express
human
receptor
day
et
al
frieman
et
al
robert
et
al
mouseadapt
sarscov
obtain
pass
viru
time
mice
excel
model
reproduc
well
patholog
caus
sarscov
human
includ
mortal
dediego
et
al
dediego
et
al
contrast
case
merscov
viru
grown
tg
knockin
human
mice
suscept
merscov
k
li
p
mccray
perlman
person
commun
first
type
merscovsuscept
mice
includ
tg
mice
express
viru
receptor
use
promot
surfact
protein
c
cytokeratin
cytomegaloviru
mice
estim
tcid
merscov
although
merscov
grow
almost
equal
well
lung
brain
tg
mice
anim
prove
use
protect
studi
zhao
et
al
tg
mous
strain
express
control
surfact
protein
c
promot
viru
found
grow
primarili
lung
might
extend
use
viral
pathogenesi
studi
c
tseng
person
commun
type
merscovsuscept
mice
avail
date
includ
knockin
strain
exon
mous
replac
homolog
sequenc
li
et
al
pascal
et
al
major
differ
tg
mice
describ
earlier
mouseadapt
merscov
produc
diseas
knockin
mice
viru
pass
time
knockin
mous
k
li
p
mccray
perlman
person
commun
wherea
merscov
mice
around
pfu
mous
anoth
mous
lineag
gener
use
technolog
alter
amino
acid
residu
known
interact
merscov
protein
lead
mice
close
reproduc
diseas
observ
human
includ
mortal
case
around
pfumous
crockrel
r
baric
person
commun
significantli
higher
observ
knockin
mice
cockrel
et
al
peck
et
al
van
doremalen
munster
k
li
p
mccray
perlman
person
commun
interestingli
knockin
mice
gener
crispr
technolog
support
merscov
replic
lung
make
extrem
use
model
pathogenesi
studi
altern
approach
rapid
gener
mous
model
merscov
transduct
mice
adenovir
vector
express
human
hostcel
receptor
mice
develop
pneumonia
character
extens
inflammatori
cell
infiltr
viru
clearanc
occur
day
infect
use
mice
efficaci
therapeut
intervent
poli
c
potenti
vaccin
base
venezuelan
equin
enceph
vee
viru
demonstr
import
advantag
approach
may
rapidli
adapt
virus
may
emerg
futur
especi
case
suitabl
mous
model
avail
vaccin
base
recombin
merscov
protein
particular
rbd
demonstr
partial
efficaci
protect
immun
macaqu
merscov
infect
reduc
pneumonia
viral
titer
sever
fragment
merscov
protein
found
induc
merscov
neutral
antibodi
respons
mice
rabbit
du
et
al
jiang
et
al
et
al
mou
et
al
similar
shown
previous
sarscov
du
et
al
wang
et
al
fragmentcontain
residu
merscov
prove
suffici
protect
mice
merscov
immunogen
fragment
improv
result
strong
humor
cellular
immun
respons
link
fragment
human
fc
use
adjuv
tang
et
al
zhang
et
al
report
confirm
merscov
protein
well
suit
develop
mer
subunit
vaccin
fulllength
protein
contain
sever
nonneutr
immunodomin
domain
may
compromis
immunogen
major
neutral
domain
induc
harm
immun
respons
demonstr
protein
sarscov
weingartl
et
al
intranas
vaccin
rbd
domain
merscov
protein
induc
much
stronger
local
mucos
immun
respons
lung
subcutan
immun
et
al
studi
show
fulllength
monomer
trimer
recombin
sarscov
merscov
protein
abl
induc
protect
respons
mice
hondaokubo
et
al
li
et
al
present
merscov
fulllength
protein
nanoparticl
combin
appropri
adjuv
elicit
neutral
antibodi
immun
mice
coleman
et
al
altern
dna
vaccin
express
fulllength
protein
smaller
fragment
effect
merscov
infect
optim
dna
vaccin
encod
fulllength
protein
merscov
elicit
antigenspecif
neutral
antibodi
mice
camel
rhesu
macaqu
six
eight
vaccin
macaqu
show
radiograph
evid
infiltr
merscov
challeng
muthumani
et
al
potent
antigenspecif
cellular
immun
respons
induc
immun
macaqu
suggest
tcell
respons
may
also
play
role
merscov
protect
two
compani
activ
work
develop
merscov
dna
vaccin
inovio
pharmaceut
inc
philadelphia
usa
geneon
life
scienc
seoul
korea
soon
perform
phase
clinic
trial
dnabas
vaccin
inovio
news
releas
http
irinoviocom
addit
dnaonli
strategi
dna
prime
protein
boost
could
altern
vaccin
approach
merscov
shown
prime
mice
nhp
dna
encod
fulllength
gene
boost
subunit
proteininduc
robust
neutral
antibodi
respons
sever
merscov
strain
protect
nhp
merscov
challeng
chimer
viruslik
particl
vlp
contain
sarscov
protein
influenza
matrix
protein
protect
mice
challeng
sarscov
liu
et
al
may
induc
strong
immun
respons
due
polymer
natur
increas
efficaci
subunit
vaccin
vlp
administ
togeth
adjuv
boll
et
al
tseng
et
al
subunit
vaccin
includ
subvir
compon
repres
full
antigen
complex
viru
result
limit
protect
efficaci
due
limit
immun
respons
case
unbalanc
immun
respons
may
lead
immunopatholog
mani
vaccin
base
chemic
inactiv
sarscov
virion
evalu
anim
model
hamster
mice
ferret
nhp
boll
et
al
iwatayoshikawa
et
al
robert
et
al
tseng
et
al
case
product
neutral
antibodi
differ
level
protect
observ
challeng
mice
sarscov
report
caus
immunopatholog
suggest
sarscov
compon
induc
hypersensit
studi
suggest
immunopatholog
lead
eosinophilia
link
least
part
viral
nucleoprotein
boll
et
al
also
immun
oligom
sarscov
protein
shown
promot
eosinophilia
follow
viral
challeng
differ
anim
model
system
tseng
et
al
suggest
potenti
side
effect
vaccin
base
inactiv
sarscov
merscov
care
evalu
prior
use
human
moreov
inactiv
wholeviru
vaccin
rais
biosafeti
concern
due
risk
vaccin
prepar
contain
infecti
viru
minim
risk
genet
attenu
virus
may
use
start
point
product
kill
viru
inactiv
vector
vaccin
gener
base
vector
proven
safeti
record
vaccin
allow
product
releas
immunogen
antigen
infect
cell
limit
period
time
vector
base
virus
differ
famili
poxviru
adenoviru
measl
togaviru
vee
use
develop
vaccin
cov
case
merscov
advanc
promis
candid
modifi
vaccinia
viru
ankara
mva
viral
vector
replic
mammalian
cell
therefor
hold
great
promis
vaccin
platform
altenburg
et
al
haagman
et
al
song
et
al
volz
et
al
use
vector
protein
fragment
differ
length
express
fulllength
extracellular
domain
rbd
case
neutral
antibodi
tcell
respons
merscov
induc
one
vector
induc
mucos
immun
reduc
shed
merscov
factor
one
thousand
challeng
virul
viru
dromedari
camel
thu
prevent
spread
anim
reservoir
haagman
et
al
mvavector
vaccin
enter
clinic
trial
support
german
center
infect
research
dzif
paddock
second
advanc
vector
vaccin
base
recombin
adenoviru
express
protein
fragment
differ
size
kim
et
al
shim
et
al
sublingu
immun
recombin
adenoviru
encod
sarscov
protein
induc
system
mucos
immun
mous
model
system
shim
et
al
system
mucos
immun
also
elicit
mice
singl
immun
human
adenoviru
type
vectorbas
vaccin
carri
protein
merscov
whether
immun
respons
confer
protect
viral
infect
remain
evalu
immun
measl
viru
vector
express
sarscov
protein
induc
neutral
antibodi
strong
respons
hallmark
liveattenu
virus
highli
desir
featur
antivir
vaccin
escriou
et
al
though
erad
measl
viru
may
repres
obstacl
applic
type
vaccin
vee
replicon
particl
express
sarscov
protein
provid
protect
lethal
homolog
heterolog
challeng
age
mice
model
sheahan
et
al
therefor
principl
sever
wellknown
vector
offer
possibl
protect
cov
infect
although
vector
base
live
virus
reason
record
safeti
limit
present
one
reduc
number
cov
antigen
immun
system
contrast
live
vaccin
base
whole
attenu
cov
consid
like
main
strategi
produc
efficaci
vaccin
near
futur
base
liveattenu
vaccin
lack
specif
virul
marker
rapid
laboratori
respons
involv
vaccin
gener
usual
achiev
use
subunit
vaccin
wholeinactiv
viru
construct
vector
vaccin
success
protect
frequent
associ
gener
strong
neutral
immun
respons
nevertheless
control
viru
emerg
type
vaccin
frequent
fail
due
rel
low
titer
shortliv
durat
neutral
antibodi
respons
time
due
induct
immun
pathogenesi
includ
eosinophilia
reaction
contrast
liveattenu
vaccin
long
histori
success
gener
immunogen
nonrepl
vaccin
produc
comprehens
spectrum
nativ
viral
antigen
prolong
time
span
present
antigen
immun
system
natur
infect
viru
attenu
favor
modern
approach
may
overcom
revers
virul
describ
later
altern
approach
design
attenu
virus
vaccin
candid
sever
laboratori
follow
identif
virulenceassoci
viral
gene
dediego
et
al
stobart
moor
totura
baric
mani
case
encod
nonessenti
immunomodulatori
protein
modif
delet
gene
lead
gener
attenu
virus
may
use
vaccin
candid
laboratori
use
strategi
extens
gener
cov
vaccin
also
group
use
approach
success
produc
vaccin
candid
influenza
respiratori
syncyti
viru
measl
dengu
mump
kirkpatrick
et
al
stobart
moor
engin
attenu
cov
vaccin
candid
requir
avail
reversegenet
system
suitabl
introduc
delet
mutat
virul
gene
well
appropri
anim
model
evalu
efficaci
safeti
candid
vaccin
date
vaccin
develop
common
human
cov
infect
nevertheless
infecti
cdna
clone
engin
three
human
cov
effici
propag
tissu
cultur
donaldson
et
al
stjean
et
al
thiel
et
al
similarli
infecti
cdna
clone
gener
sarscov
almazan
et
al
yount
et
al
merscov
almazan
et
al
scobey
et
al
provid
excel
basi
ration
develop
liveattenu
vaccin
base
recombin
virus
virul
cov
gener
associ
specif
virul
gene
case
antagon
cellular
innat
immun
respons
requir
effici
viru
replic
cov
infect
affect
mani
hostcel
pathway
modul
pathogenesi
innat
immun
respons
first
line
hostcel
defens
virus
viral
factor
modul
pathway
may
strong
impact
pathogenesi
cov
protein
activ
involv
format
host
membran
vesicl
structur
affect
cov
replic
evas
immun
system
hide
doublestrand
rna
dsrna
gener
viru
replic
angelini
et
al
pathogenassoci
molecular
pattern
pamp
ssrna
dsrna
viral
protein
trigger
activ
transcript
factor
lead
proinflammatori
cytokin
type
ifn
induct
pamp
activ
protein
kinas
rnaactiv
lead
translat
initi
factor
phosphoryl
inhibit
host
translat
oligoadenyl
synthas
oa
trigger
rnase
l
rna
degrad
fig
activ
cytoplasm
sensor
rigi
trigger
upregul
ifn
regulatori
factor
irf
nuclear
factor
kappalightchainenhanc
activ
b
cell
nfkb
mitochondri
antiviralsign
protein
fig
addit
tolllik
receptor
tlr
activ
respons
protein
adaptor
molecul
trifdepend
pathway
also
upregul
transcript
factor
nfkb
activ
protein
fig
dediego
et
al
cov
protein
act
ifn
antagonist
inhibit
product
signal
fig
dediego
et
al
totura
baric
zhong
et
al
potent
cytokin
involv
control
viral
infect
prime
adapt
immun
respons
gener
respons
cov
infect
totura
baric
zhou
et
al
howev
uncontrol
induct
proinflammatori
cytokin
also
increas
pathogenesi
diseas
sever
describ
sarscov
merscov
dediego
et
al
b
seling
et
al
cellular
pathway
mediat
activ
transcript
factor
atf
nfkb
nuclear
factor
activ
cell
main
driver
inflammatori
respons
trigger
sarscov
infect
nfkb
pathway
strongli
activ
dediego
et
al
cov
protein
elicit
type
innat
immun
respons
may
modifi
gener
attenu
virus
suitabl
vaccin
develop
human
cov
abl
suppress
ifn
induct
differ
extent
gener
sensit
addit
exogen
ifn
kindler
et
al
sarscov
particular
highli
resist
antivir
state
induc
ifn
treatment
suggest
possess
mani
mechan
counteract
ifninduc
antivir
respons
zielecki
et
al
betacoronaviru
except
sensit
human
cov
ifn
infect
certain
cell
type
viru
favor
presenc
exogen
ifn
possibl
explan
observ
may
use
ifninduc
transmembran
ifitm
protein
cell
entri
zhao
et
al
interestingli
antivir
activ
observ
alphacoronavirus
betacoronavirus
sarscov
merscov
wrensch
et
al
suggest
ifitm
protein
may
posit
effect
betacoronaviru
infect
number
nsp
implic
human
cov
pathogenesi
possibl
might
use
produc
highli
attenu
strain
common
human
cov
vaccin
candid
protein
encod
member
alphacoronaviru
betacoronaviru
genera
similar
function
case
despit
lowsequ
conserv
protein
inhibit
protein
express
like
via
associ
ribosom
subunit
also
act
ifn
antagonist
zust
et
al
transmembran
replicas
protein
contain
sever
function
domain
fig
conserv
among
common
human
cov
two
papainlik
proteas
plp
two
ubiquitinlik
domain
phosphatas
adrp
domain
role
adrp
pathogenesi
human
cov
propos
although
requir
fig
multidomain
structur
cov
nonstructur
protein
approxim
boundari
domain
sarscov
protein
indic
underneath
amino
acid
number
replicas
polyprotein
ac
glurich
acid
domain
adpr
phosphatas
also
call
macrodomain
x
domain
nab
nucleic
acidbind
domain
sud
sarsuniqu
domain
transmembran
domain
form
addit
domain
contain
metalbind
region
zf
ubl
ubiquitinlik
domain
domain
preced
ctermin
plp
cleavag
sequenc
viral
growth
cell
cultur
sarscov
mutant
lack
adrp
activ
grow
similar
titer
compar
wildtyp
virus
vero
cell
respect
kuri
et
al
putic
et
al
adrpdefici
mutant
mous
hepat
viru
mhv
attenu
vivo
probabl
due
defici
induct
proinflammatori
respons
eriksson
et
al
adrp
mutant
sarscov
report
sensit
ifn
compar
wildtyp
virus
suggest
adrp
activ
involv
counteract
ifn
activ
kuri
et
al
plp
domain
also
link
modul
innat
immun
respons
domain
extens
character
act
ifn
antagonist
clementz
et
al
apart
plp
activ
deubiquitin
dub
deisgyl
activ
chen
et
al
clementz
et
al
dub
activ
seem
involv
modul
nfkb
activ
clementz
et
al
modul
ifn
product
takaoka
et
al
deubiquitin
cellular
protein
lead
proteasom
degrad
consequ
decreas
ifn
product
yuan
et
al
ribos
omethyltransferas
omtas
activ
requir
produc
structur
viral
rna
methyl
prove
import
avoid
viral
rna
recogn
nonself
hostcel
sensor
subsequ
activ
cellular
innat
immun
respons
mutant
lack
omtas
activ
replic
fold
lower
titer
wildtyp
viru
cell
confirm
relev
activ
moreov
omtas
mutant
sensit
treatment
type
ifn
macrophag
infect
mutant
viru
produc
type
ifn
infect
parent
viru
role
modul
innat
immun
seem
conserv
among
cov
similar
result
obtain
mhv
sarscov
sarscov
mutant
lack
omtas
activ
attenu
vivo
cov
contain
variabl
number
genusspecif
gene
implic
modul
pathogenesi
fact
common
human
cov
contain
genusspecif
gene
locat
envelop
e
gene
name
fig
gene
encod
transmembran
protein
differ
significantli
sequenc
predict
structur
muller
et
al
zhang
et
al
zhang
et
al
may
relat
function
ion
channel
activ
morphogenesi
donaldson
et
al
zhang
et
al
zhang
et
al
fact
sarscov
protein
protein
protein
abl
complement
tran
absenc
protein
protein
essenti
viral
growth
cell
cultur
viru
yield
increas
protein
express
also
evid
protein
homolog
may
play
import
role
vivo
exampl
clinic
isol
contain
fulllength
cell
cultureadapt
strain
gene
spontan
divid
two
orf
replac
truncat
orf
encod
first
transmembran
domain
recombin
viru
grow
lower
titer
parent
viru
primari
human
airway
epithelium
hae
cultur
donaldson
et
al
final
recombin
viru
attenu
vivo
result
suggest
gene
modifi
gener
attenu
virus
may
use
vaccin
candid
gene
predict
encod
phosphodiesteras
pde
base
homolog
mhv
gene
rothcross
et
al
mhv
proteinmedi
pde
activ
interfer
oasrnas
l
pathway
affect
pathogenesi
counteract
cellular
innat
immun
respons
zhao
et
al
moreov
absenc
pde
activ
complement
viral
cellular
pde
common
human
betacoronavirus
encod
hemagglutininesteras
gene
fig
protein
transmembran
protein
incorpor
viral
envelop
act
receptordestroy
enzym
role
viral
entri
huang
et
al
interestingli
mutant
lack
gene
encod
inact
protein
produc
replicationcompet
propagationdefect
virus
desforg
et
al
virus
principl
may
use
vaccin
candid
sarscov
encod
mani
known
immunomodulatori
protein
membran
e
nucleocapsid
n
fig
dediego
et
al
dediego
et
al
totura
baric
zhong
et
al
modif
delet
may
lead
attenu
virus
could
use
live
vaccin
candid
mani
protein
also
specif
inhibit
cellular
signal
pathway
associ
innat
immun
respons
gener
thought
delet
genet
modif
sarscov
gene
encod
protein
ifn
antagonist
activ
viral
defens
mechan
n
result
attenu
virus
shown
sarscov
mutant
respect
altern
approach
produc
attenu
cov
use
vaccin
candid
modif
viral
replic
fidel
propos
graham
et
al
smith
et
al
liveattenu
rna
viru
vaccin
efficaci
subject
revers
virul
among
rna
virus
replic
fidel
recogn
key
determin
virul
escap
antivir
therapi
though
reduc
fidel
detriment
virus
replic
fidel
cov
estim
approxim
higher
rna
virus
mediat
exonucleas
exon
activ
minskaia
et
al
probabl
function
rna
proofread
eckerl
et
al
demonstr
engin
abrog
sarscov
exon
activ
result
stabl
mutat
phenotyp
profoundli
decreas
fidel
cell
cultur
vivo
attenu
pathogenesi
young
age
immunocompromis
mice
graham
et
al
exon
null
genotyp
mutat
phenotyp
stabl
revert
virul
even
serial
passag
longterm
persist
infect
vivo
exon
inactiv
thu
potenti
broad
applic
stabl
attenu
cov
laboratori
focus
role
virul
sarscov
e
protein
merscov
e
protein
studi
effect
partial
complet
delet
viru
attenu
possibl
implic
vaccin
develop
dediego
et
al
dediego
et
al
reglanava
et
al
safeti
vaccin
candid
enhanc
genet
modif
sequenc
cov
e
protein
aa
length
depend
viru
divers
function
cov
morphogenesi
secretori
pathway
westerbeck
macham
import
e
differ
cov
speci
genera
vari
greatli
rang
absolut
essenti
member
genera
alphacoronaviru
tgev
betacoronaviru
lineag
c
merscov
nonessenti
function
betacoronavirus
mhv
lineag
sarscov
lineag
b
sarscov
two
strategi
use
abrog
e
function
complet
delet
e
protein
introduct
small
delet
aa
e
protein
carboxylterminu
similar
strategi
current
appli
merscov
j
gutierrez
sola
l
enjuan
unpublish
result
sarscov
e
protein
nonessenti
viru
replic
dissemin
delet
led
attenu
form
sarscov
promis
vaccin
candid
see
later
viral
infect
often
induc
endoplasm
reticulum
er
stress
specif
unfold
protein
respons
upr
upr
induc
three
main
signal
pathway
avoid
accumul
protein
alter
fold
er
stress
er
also
interconnect
innat
immun
respons
hostcel
respons
hetz
induc
er
stress
mechan
associ
protein
express
lead
virul
cov
mous
model
favreau
et
al
siu
et
al
similarli
case
sarscov
e
protein
link
virul
induct
upr
dediego
et
al
e
protein
major
role
inflammasom
activ
associ
exacerb
inflamm
elicit
sarscov
lung
parenchyma
exacerb
inflamm
caus
edema
lead
acut
respiratori
distress
syndrom
frequent
death
experiment
infect
anim
human
patient
e
protein
viroporin
conduct
ca
ion
chang
intracellular
ca
concentr
mediat
e
protein
ion
channel
activ
respons
inflammasom
activ
elimin
ion
channel
activ
introduct
aa
substitut
within
transmembran
domain
e
protein
led
viru
attenu
carboxylterminu
e
protein
contain
anoth
virul
factor
pdz
domainbind
motif
pbm
sarscov
infect
could
potenti
target
cellular
protein
contain
pdz
domain
possibl
effect
viral
pathogen
interestingli
delet
modif
e
protein
pbm
result
attenu
sarscov
good
vaccin
candid
reglanava
et
al
delet
fulllength
e
protein
led
attenu
sarscov
sever
anim
model
lamirand
et
al
netland
et
al
immunogen
protect
efficaci
liveattenu
vaccin
base
recombin
sarscov
lack
e
gene
e
first
studi
use
hamster
immun
hamster
develop
high
serum
neutral
antibodi
titer
protect
challeng
homolog
sarscov
urbani
heterolog
sarscov
upper
lower
respiratori
tract
delet
e
protein
modestli
diminish
viral
growth
cell
cultur
abrog
virul
mice
netland
et
al
shown
immun
almost
complet
protect
balbc
mice
fatal
respiratori
diseas
caus
mouseadapt
sarscov
partli
protect
tg
mice
lethal
diseas
although
tg
mice
express
human
sarscov
receptor
extrem
suscept
infect
furthermor
also
show
induc
antivir
tcell
antibodi
respons
improv
vaccin
efficaci
engin
adapt
rsarscov
effici
grow
mice
end
incorpor
six
nucleotid
substitut
sarscov
genom
frieman
et
al
robert
et
al
use
reversegenet
system
base
bacteri
artifici
chromosom
use
rsarscovma
backbon
genom
second
set
edelet
vaccin
candid
gener
fett
et
al
safe
caus
diseas
balbc
mice
immun
viru
complet
protect
mice
three
age
lethal
diseas
induc
rapid
viru
clearanc
compar
e
immun
elicit
significantli
greater
neutral
antibodi
titer
virusspecif
tcell
respons
challeng
inflammatori
cell
infiltr
edema
cell
destruct
decreas
lung
mice
compar
mice
suggest
mouseadapt
viru
safe
candid
vaccin
identifi
e
protein
domain
contribut
e
attenu
sever
rsarscov
mutat
delet
e
protein
gener
substitut
amino
terminu
delet
region
intern
carboxytermin
region
e
protein
led
viru
attenu
attenu
virus
induc
minim
lung
injuri
diminish
edema
limit
neutrophil
influx
increas
tcell
count
lung
balbc
mice
compar
anim
infect
wildtyp
viru
attenu
virus
complet
protect
mice
challeng
lethal
parent
viru
consider
increas
surviv
infect
anim
indic
virus
promis
vaccin
candid
ideal
vaccin
provid
full
protect
case
sarscov
vaccin
candid
engin
delet
fulllength
e
protein
nevertheless
good
vaccin
must
also
genet
stabl
initi
vaccin
unstabl
cell
cultur
vivo
fact
mutant
viru
regain
fit
serial
passag
cell
cultur
result
partial
duplic
membran
gene
chimer
protein
increas
viral
fit
vitro
viru
remain
attenu
mice
fulllength
e
gene
delet
pbm
code
sequenc
mutat
revert
virus
either
evolv
novel
chimer
gene
includ
pbm
restor
sequenc
pbm
e
protein
respect
passag
mice
viru
incorpor
mutant
variant
protein
includ
pbm
result
revers
virul
phenotyp
data
addit
evid
led
us
conclud
viru
requir
pbm
transmembran
protein
compens
remov
motif
e
protein
therefor
increas
genet
stabil
vaccin
candid
introduc
small
attenu
delet
e
gene
affect
endogen
pbm
prevent
select
revert
incorpor
novel
pbm
viru
genom
lead
genet
function
stabl
vaccin
candid
increas
vaccin
safeti
introduc
addit
attenu
amino
acid
substitut
protein
recombin
virus
includ
attenu
mutat
e
sequenc
maintain
attenu
passag
vitro
vivo
furthermor
virus
fulli
protect
mice
challeng
lethal
parent
viru
therefor
safe
stabl
vaccin
candid
protect
sarscov
jimenezguardeno
et
al
relev
merscov
protein
modul
cellular
innat
immun
respons
vari
depend
experiment
approach
use
two
main
strategi
appli
either
express
individu
viru
protein
delet
appropri
proteincod
sequenc
fulllength
viru
genom
use
first
approach
overexpress
merscov
protein
human
transfect
cell
structur
accessori
protein
identifi
potenti
ifn
antagonist
matthew
et
al
yang
et
al
contrast
role
viru
protein
analyz
cell
infect
merscov
delet
mutant
individu
gene
respect
delet
observ
among
protein
major
antagonist
innat
immun
respons
induct
j
canton
perlman
l
enjuan
sola
unpublish
result
delet
result
merscov
mutant
increas
inf
sensit
effect
may
associ
dsrnabind
domain
protein
shown
interact
pact
rnadepend
manner
therebi
reduc
activ
rigi
overexpress
assay
siu
et
al
also
combin
delet
accessori
gene
recombin
merscov
show
log
reduct
viral
titer
compar
fulllength
merscov
scobey
et
al
therefor
engin
merscov
delet
one
gene
could
lead
promis
vaccin
candid
complet
delet
e
gene
merscov
led
gener
replicationcompet
propagationdefect
virus
promis
vaccin
candid
almazan
et
al
e
protein
induc
cell
apoptosi
et
al
dediego
et
al
establish
stabl
cell
line
constitut
express
protein
complement
virus
lack
e
protein
possibl
overcom
limit
gener
packag
cell
line
transient
express
e
protein
induc
manner
use
grow
replicationcompet
propagationdefect
j
gutierrezalvarez
sola
l
enjuan
unpublish
result
addit
fulli
stabl
transform
mammalian
cell
gener
e
protein
express
control
optim
teton
system
doxycyclineinduc
gene
express
drastic
reduc
leaki
express
da
et
al
markus
et
al
j
gutierrez
sola
l
enjuan
unpublish
result
altern
strategi
replicationand
propagationeffici
rmerscov
gener
express
slightli
shorten
e
protein
lack
aa
carboxylterminu
previous
report
sarscov
vaccin
candid
j
gutierrezalvarez
perlman
sola
l
enjuan
unpublish
result
thu
lesson
learn
previou
sarscov
vaccin
biosafeti
studi
use
attenu
virus
express
shorten
e
protein
see
earlier
may
also
applic
engin
merscov
vaccin
merscov
replicas
protein
possibl
may
also
interfer
signal
pathway
associ
innat
immun
respons
differ
mechan
yang
et
al
therefor
modif
delet
replicas
gene
sequenc
encod
protein
may
also
lead
gener
attenu
virus
similar
sarscov
inhibit
host
gene
express
translat
level
report
merscov
exhibit
conserv
function
inhibit
host
mrna
translat
induc
host
mrna
degrad
inform
could
exploit
produc
merscov
vaccin
candid
common
human
cov
sarscov
merscov
plp
deisgyl
dub
activ
act
interferon
antagonist
barretto
et
al
chen
et
al
clementz
et
al
frieman
et
al
ratia
et
al
zheng
et
al
mutat
introduc
merscov
plp
code
sequenc
specif
disrupt
ubiquitin
bind
without
affect
viral
polyprotein
cleavag
led
plp
variant
without
dub
activ
lost
wildtyp
abil
inhibit
promot
activ
report
assay
find
directli
implic
dub
deisgyl
function
plp
inhibit
promot
activ
modif
may
lead
attenu
merscov
addit
plp
catalyt
activ
requir
merscov
sarscov
reduc
induct
endogen
proinflammatori
cytokin
infect
cell
mielech
et
al
consist
import
function
ubiquitin
modif
cellular
protein
interferonstimul
gene
regul
cellular
innat
immun
pathway
hand
shown
sarscov
plp
interfer
format
signal
complex
includ
sting
stimul
interferon
gene
thu
prevent
downstream
phosphoryl
dimer
nuclear
transloc
mediat
sting
fig
yang
et
al
inhibit
depend
plp
catalyt
activ
studi
provid
valuabl
inform
merscov
plpmediat
antagon
host
innat
immun
respons
orchestr
offer
addit
attract
option
design
attenu
virus
vaccin
candid
gener
subunit
vaccin
sarscov
merscov
administ
without
adjuv
provid
differ
degre
protect
haagman
et
al
jaum
et
al
wang
et
al
howev
mention
earlier
vaccin
use
caution
human
possibl
adei
mechan
especi
antibodi
level
low
highli
concentr
antisera
sarscov
shown
neutral
viru
infect
wherea
dilut
monoand
polyclon
anti
protein
antibodi
caus
adei
human
promonocyt
cell
cultur
lead
cytopath
effect
increas
level
haagman
et
al
jaum
et
al
wang
et
al
addit
document
immun
mice
vlp
inactiv
viru
presenc
absenc
adjuv
induc
eosinophil
immunopatholog
young
age
mice
boll
et
al
tseng
et
al
use
doubleinactiv
sarscov
vaccin
protect
observ
homolog
heterolog
challeng
protect
nonleth
heterolog
challeng
poor
enhanc
immun
patholog
compar
seen
sarscov
n
proteinimmun
mice
importantli
age
mice
display
increas
eosinophil
immun
patholog
lung
mice
protect
significantli
viru
replic
induct
immunopatholog
also
observ
challeng
ferret
nhp
immun
candid
vaccin
base
vlp
wholeinactiv
sarscov
viru
rdnaproduc
protein
tseng
et
al
pulmonari
damag
challeng
sarscov
associ
immunopatholog
promin
eosinophil
infiltr
upregul
gene
associ
induct
eosinophilia
observ
interestingli
immunopatholog
lung
upon
sarscov
infect
could
avoid
administr
tlr
agonist
adjuv
iwatayoshikawa
et
al
increas
durat
immun
respons
elicit
vaccin
prevent
covinduc
lung
immunopatholog
observ
challeng
natur
infect
effect
adjuv
studi
immun
either
recombin
cov
protein
inactiv
wholeviru
vaccin
effect
differ
adjuv
includ
alum
cpg
adva
new
deltainulinbas
polysaccharid
adjuv
analyz
hondaokubo
et
al
vaccin
protect
lethal
infect
addit
adjuv
significantli
increas
serum
neutral
antibodi
titer
reduc
lung
viru
titer
day
postchalleng
wherea
adjuvantfre
alumformul
vaccin
associ
signific
increas
lung
eosinophil
immunopatholog
day
postchalleng
seen
mice
immun
vaccin
formul
deltainulin
adjuv
absenc
eosinophil
immunopatholog
vaccin
contain
deltainulin
adjuv
found
correspond
enhanc
tcell
respons
rather
reduc
respons
suggest
immunopatholog
primarili
caus
inadequ
vaccineinduc
respons
illustr
need
induc
durabl
respons
use
appropri
adjuv
possibl
product
infect
macrophag
dendrit
cell
dc
merscov
debat
wherea
report
provid
evid
infect
human
dc
tabl
chu
et
al
scheuplein
et
al
ying
et
al
other
abl
product
grow
viru
tg
miceexpress
c
tseng
person
commun
differ
origin
cell
might
explain
diverg
result
work
need
clarifi
suscept
dc
merscov
common
human
cov
well
highli
pathogen
sarscov
merscov
infect
ciliat
epitheli
cell
hae
cultur
wherea
infect
noncili
cell
dijkman
et
al
kindler
et
al
human
cov
elicit
product
proinflammatori
cytokin
human
primari
respiratori
epitheli
cell
ex
vivo
human
lung
tissu
cultur
product
type
iii
ifn
consist
found
low
chan
et
al
kindler
et
al
zielecki
et
al
suggest
human
cov
evolv
mechan
antagon
host
innat
immun
respons
mediat
varieti
viral
protein
epitheli
cell
dc
play
role
viru
replic
lung
may
impact
pathogenesi
infect
although
former
effici
collin
patterson
macnaughton
dc
serv
sentinel
respiratori
tract
connect
innat
adapt
immun
lung
effici
infect
kill
dc
propos
potenti
mechan
delay
host
adapt
immun
provid
time
replic
host
mesellemoin
et
al
interact
merscov
human
dc
chu
et
al
scheuplein
et
al
ying
et
al
induc
merscov
also
infect
mous
monocytederiv
dendrit
cell
induc
although
margin
level
detect
zhou
et
al
contrast
human
plasmacytoid
dendrit
cell
merscov
induc
larg
amount
type
iii
ifn
especi
scheuplein
et
al
although
infect
abort
sarscov
also
infect
human
dc
viral
replic
abort
infecti
viru
particl
produc
law
et
al
tseng
et
al
yilla
et
al
ziegler
et
al
despit
lack
product
infect
human
sarscov
induc
express
proinflammatori
chemokin
includ
contrast
antivir
cytokin
basic
absent
law
et
al
law
et
al
tseng
et
al
unproduct
infect
dc
sarscov
induc
apoptosi
lymphopenia
ifniii
sarscov
abor
abor
prod
abor
apoptosi
lymphopenia
ifniii
law
et
al
tseng
et
al
dysregul
type
ifn
inflammatori
respons
sarscovinfect
mice
result
high
level
cytokin
chemokin
impair
virusspecif
tcell
respons
lead
lethal
pneumonia
merscov
sarscov
infect
human
primari
cell
induc
massiv
apoptosi
lymphopenia
although
produc
infecti
viru
cell
chu
et
al
gu
et
al
zhou
et
al
infect
cell
may
play
role
control
pathogenesi
elicit
merscov
sarscov
similarli
field
virus
live
sarscov
merscov
vaccin
may
interact
host
dc
promot
synthesi
cytokin
chemokin
could
lead
undesir
side
effect
includ
imbalanc
proinflammatori
immun
respons
analysi
type
interleukin
cytokin
produc
vaccin
administr
includ
safeti
studi
candid
vaccin
could
involv
murin
leukocyt
deriv
suscept
tg
mice
human
cell
collect
healthi
donor
despit
extens
effort
commenc
sar
epidem
antivir
drug
suitabl
treat
cov
infect
approv
fda
barnard
kumaki
kilianski
baker
nevertheless
sever
antivir
compound
preclin
develop
may
use
control
human
cov
infect
adedeji
sarafiano
zumla
et
al
number
compound
target
highli
conserv
replicas
protein
therefor
effect
broad
rang
cov
includ
common
human
cov
key
enzymat
activ
viral
main
proteas
plp
helicas
employ
target
covspecif
antivir
drug
conserv
antivir
target
gener
thought
toler
fewer
mutat
compar
structur
protein
gene
due
higher
fit
pressur
thu
possibl
reduc
risk
resist
variant
emerg
rapidli
antivir
treatment
compound
inhibit
viru
entri
morphogenesi
also
test
though
except
viral
life
cycl
step
poor
antivir
target
escap
mutant
easili
recov
especi
viral
structur
protein
target
cell
attach
inhibit
differ
antibodi
combin
subsequ
step
cell
entri
inhibit
proteinderiv
heptadrepeat
peptid
case
similarli
inhibitor
vacuolar
acidif
effect
cell
cultur
cell
vivo
keyaert
et
al
pyrc
et
al
identif
signal
pathway
involv
sarscovmedi
pathogenesi
provid
select
system
drug
significantli
increas
surviv
infect
mice
exampl
identif
nfkb
main
signal
pathway
lead
exacerb
inflammatori
respons
sarscov
infect
enabl
select
antivir
suitabl
control
infect
dediego
et
al
similarli
identif
increas
phosphoryl
mapk
sarscov
e
proteinactiv
syntenin
also
led
dramat
increas
surviv
infect
mice
treat
mapk
inhibitor
fig
e
sarscov
envelop
protein
ecm
extracellular
matrix
fak
signal
adhes
kinas
protein
mock
noninfect
mice
p
phosphoryl
residu
mapk
map
kinas
inhibitor
mapk
wt
mice
infect
virul
sarscov
new
anim
human
cov
constantli
emerg
reemerg
anim
reservoir
maintain
includ
bat
bird
present
high
number
high
mobil
consequ
develop
technolog
suitabl
respond
swiftli
newli
emerg
cov
produc
vaccin
highli
desir
goal
could
achiev
product
subunit
inactiv
vaccin
optim
combin
antigen
adjuv
need
establish
minim
risk
adei
eosinophilia
frequent
occur
cov
vaccin
develop
past
believ
vaccin
futur
mainli
base
liveattenu
virus
superior
potenti
induc
balanc
immun
respons
potent
longlast
immun
comprehens
b
tcell
repertoir
induc
type
vaccin
howev
develop
safe
liveattenu
viru
vaccin
requir
strong
experiment
support
confirm
suffici
attenu
target
speci
possibl
result
longer
develop
product
time
